Neuroma

Summary

Neuroma (MONDO:0002173) is a disease and 17 clinical trials. Top therapeutic interventions include indocyanine green acid form, bupivacaine, and capsaicin. A subtype of peripheral nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neuroma
Mondo ID	MONDO:0002173
EFO	EFO:0009619
MeSH	D009463
DOID	DOID:2001
NCIT	C3275
SNOMED CT	443892003
UMLS	C0027858
MedGen	14352
Anatomy (UBERON)	UBERON:0001021
Is cancer (heuristic)	no

Disease family

This is a subtype of peripheral nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › neuroma

Related subtypes (17): autoimmune disorder of peripheral nervous system, autonomic nervous system disorder, peripheral nervous system neoplasm, vestibulocochlear nerve disorder, hypoglossal nerve disorder, facial nerve disorder, accessory nerve disorder, glossopharyngeal nerve disorder, olfactory nerve disorder, radiculopathy, trigeminal nerve disorder, third cranial nerve disorder, peripheral neuropathy, cauda equina syndrome, peroneal nerve paralysis, trochlear nerve disorder, abducens nerve disorder

Subtypes (2): multiple mucosal neuroma, Morton neuroma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Capsaicin, Onabotulinumtoxina.

Clinical trials & evidence

Clinical trials

Clinical trials: 17.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	12
PHASE2	3
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01632709	PHASE4	COMPLETED	Pathophysiology of Post Amputation Pain
NCT06164392	PHASE4	WITHDRAWN	Evaluation of Neuroma Perfusion with Indocyanine Green Fluorescence Angiography
NCT06915662	PHASE2	RECRUITING	Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap
NCT00130962	PHASE2	COMPLETED	ALGRX 4975 in the Treatment of Patients With Morton’s Neuroma
NCT01374191	PHASE2	WITHDRAWN	Botulinum Toxin Type A for Neuroma Pain
NCT05008185	Not specified	RECRUITING	Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation
NCT07416448	Not specified	RECRUITING	Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine
NCT02205385	Not specified	COMPLETED	Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation
NCT02316262	Not specified	COMPLETED	Targeted Reinnervation for Neuromas as a Means to Improve Prosthesis Control in Major Limb Amputation
NCT02528266	Not specified	COMPLETED	Surgical Treatment of Symptomatic Neuroma Stop Neuroma
NCT02930551	Not specified	COMPLETED	Neuromas as the Cause of Pain
NCT02993276	Not specified	COMPLETED	Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma
NCT03051113	Not specified	COMPLETED	Identification of Neuromas by High Resolution Ultrasound in Patients With Peripheral Nerve Injury and Amputations
NCT03484429	Not specified	COMPLETED	Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain
NCT04931056	Not specified	COMPLETED	A Post Market Clinical Follow-up Study on Biomet Microfixation HTR PEKK (Midface), Facial & Mandibular Plates.
NCT06923566	Not specified	COMPLETED	Targeted Muscle Reinnervation in the Hand for the Managment of Symptomatic Neuroma Following Digit and Hand Amputations
NCT07360730	Not specified	COMPLETED	High-Purity Type I Collagen Nerve Wrapping in Peripheral Nerve Procedures: A Prospective Registry

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
INDOCYANINE GREEN ACID FORM	4	2
BUPIVACAINE	4	1
CAPSAICIN	4	1